BioPharmSignal logoBioPharmSignal

Biotech News

Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Xenon (XENE)XenonCompany update

VANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced

Related news

XENEXenon2026-11-03 21:01 EST

Xenon to Present at Upcoming Investor Conferences

XENEXenon2026-09-03 20:01 EST

Xenon to Present at Wells Fargo Healthcare Conference

NBIXNeurocrine Biosciences2026-11-03 21:05 EST

Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress

TNXPTonix Pharmaceuticals2026-11-04 12:00 EST

Tonix Pharmaceuticals to Present at Guggenheim’s 3rd Annual Healthcare Innovation Conference

ABOSAcumen Pharmaceuticals2026-10-22 11:30 EST

Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

TNXPTonix Pharmaceuticals2026-10-19 11:00 EST

Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain

CGTXCognition Therapeutics2026-09-08 11:30 EST

Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference

HRMYHarmony Biosciences2026-09-03 12:05 EST

Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

VYGRVoyager Therapeutics2026-09-01 12:00 EST

Voyager to Present at Upcoming Investor Conferences

GANXGain Therapeutics2026-10-08 11:00 EST

Gain Therapeutics to Attend the 2026 Maxim Growth Summit

View all latest news

Xenon

Ion-Channel Therapeutics Xenon Pharmaceuticals develops medicines that modulate neuronal ion channels. Its pipeline addresses epilepsy, depression and pain through mechanisms intended to control abnormal electrical signaling. Azetukalner Azetukalner is a selective Kv7 potassium-channel opener intended to reduce excessive neuronal firing....

Recent company news

XENEXenon2026-11-03 21:01 EST

Xenon to Present at Upcoming Investor Conferences

XENEXenon2026-11-02 21:02 EST

Xenon to Report Q3 2026 Financial Results on November 9, 2026

XENEXenon2026-10-30 20:01 EST

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XENEXenon2026-10-29 12:30 EST

Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain

XENEXenon2026-10-02 20:01 EST

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
37.68 USD
Market cap
5.06B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States